SEC Form 4 · accession 0001853327-26-000008
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott L Burrows
Officer — Chief Financial Officer
Period of report
Jun 25, 2026
Accepted (ET)
Jun 26, 2026 · 9:31 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 25, 2026 | M | 15,000 | $14.50 | A | 112,994 | D | |
| Common Stock | Jun 25, 2026 | S | 5,000 | $87.12 | D | 107,994 | D | |
| Common StockF1,F2 | Jun 25, 2026 | S | 10,000 | $87.14 | D | 97,994 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $14.50 | Jun 25, 2026 | M | 15,000 | D | — | Sep 1, 2033 | Common Stock | 15,000 | 359,857 | D |
Explanation of responses
- F1The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.78 to $87.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F2Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
- F3This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.